Key facts
- GeekGene’s last known valuation is $66.7M (Jun 2025).
- It has raised $2.8M; the latest was Later Stage VC ($2.8M) in Jun 2025.
- Notable investors include WinDigital Capital Management, BrightGene Bio-Medical Technology Company, Guoqian Venture Capital, JuCreate, Qihang Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for GeekGene
- ·The full record, as it builds
Funding rounds
No funding rounds for GeekGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeekGene
Developer of innovative cellular drugs designed for treatment of cancer and other severe diseases. The company engages in the preparation of high-quality T cells for the treatment of mid- to late-stage solid tumors, providing medical industry users with innovative oncology medicals.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- geekgene.com.cn/
- Ownership
- Privately Held (backing)
GeekGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeekGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeekGene in its N-PORT filings yet. We sweep new filings monthly.